OS Therapies Prepares for a Major Presentation at LD Micro
OS Therapies (NYSE American: OSTX) is poised to make significant strides in the field of oncology at the upcoming LD Micro Main Event XVII. This event serves as a prime opportunity for the company to spotlight its innovative advancements in immunotherapy and the development of Antibody Drug Conjugates. Paul Romness, the Chief Executive Officer, alongside Gerald Commissiong, Chief Business Officer, will lead the presentation, sharing insights into the company's vision and upcoming projects.
Event Details for LD Micro Main Event XVII
The LD Micro Main Event XVII is a well-regarded conference drawing together prominent players in the market. Slated for October 28-30, 2024, at the Luxe Sunset Boulevard Hotel, Los Angeles, this event offers a rich platform for networking and investment discussions.
When and Where to Watch
Mr. Romness and Mr. Commissiong will present on Tuesday, October 29, 2024, at 11:30 AM PT. Attendees can expect an engaging overview of OS Therapies’ strategies and clinical results, particularly focusing on their lead product, OST-HER2. This session aims to illuminate the company’s potential and how it plans to revolutionize treatments for Osteosarcoma and other solid tumors.
How to Register for Viewing the Presentation
To watch the presentation, interested parties must register. Following their registration, attendees will have the chance to engage directly with OS Therapies' leadership during one-on-one meetings after the presentation. This direct interaction will allow registered investors to gain a deeper understanding of the company's ambitions and answers to their inquiries.
About OS Therapies
OS Therapies is dedicated to pioneering solutions for cancer treatment, particularly for challenging diseases like Osteosarcoma. At the heart of their operations is OST-HER2—a cutting-edge immunotherapy that harnesses Listeria bacteria to stimulate immune responses specifically against the HER2 protein. The company’s commitment is evident as they are wrapping up a Phase 2b clinical trial, with results expected to be unveiled in late 2024.
Investing in the Future of Cancer Treatment
In addition to OST-HER2, OS Therapies is enhancing its pipeline with the next-generation Antibody Drug Conjugate platform known as tunable ADC (tADC). This platform utilizes advanced silicone linker technology to tailor multiple therapies, embodying OS Therapies’ innovative approach to targeting and treating cancer effectively.
Conclusion and Future Prospects
As OS Therapies prepares for its presentation at LD Micro Main Event XVII, industry professionals and investors alike are keen to witness the insights and updates being shared. The focus will be on their breakthroughs in immunotherapy that promises to make a significant impact on the lives of patients battling difficult cancers.
Frequently Asked Questions
What is OS Therapies known for?
OS Therapies specializes in developing novel treatments for Osteosarcoma and other solid tumors through innovative immunotherapy approaches.
What will be presented at LD Micro Main Event XVII?
OS Therapies will provide an overview of their corporate strategy, recent developments, and the status of their clinical trials.
When is OS Therapies' presentation scheduled?
The presentation is set for October 29, 2024, at 11:30 AM PT.
How can I attend the presentation?
To watch the presentation, you’ll need to register for the LD Micro Main Event XVII.
What is OST-HER2?
OST-HER2 is OS Therapies' leading immunotherapy candidate targeting the HER2 protein, currently undergoing clinical evaluation.
